Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01293500
Other study ID # 1R21HD060171-01A2
Secondary ID
Status Terminated
Phase N/A
First received October 22, 2010
Last updated May 3, 2016
Start date October 2010
Est. completion date November 2014

Study information

Verified date May 2016
Source Arkansas Children's Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

Recent advances in critical care medicine have dramatically improved morbidity and mortality of critical illness. Goal-directed therapy protocols have been instrumental in this change. Goal-directed therapy standardizes the rapid delivery of definitive care in illnesses such as SIRS (Systemic Inflammatory Response Syndrome) and head trauma. Although this treatment approach has been shown to improve clinical outcomes, it has not been widely adopted outside academic medical centers. Further improvement in outcomes of critical illness is likely if goal-directed therapy is utilized early in the course of care. To facilitate this early adoption, goal-directed therapeutic protocols should be developed and implemented by specialized pediatric transport teams. The investigators hypothesize that the institution of goal-directed therapy during pediatric interfacility transport will improve the outcomes of critically ill children.

The GRIPIT Trial (Goal-directed Resuscitative Interventions during Pediatric Inter-facility Transport) will compare outcomes of pediatric SIRS patients before and after the implementation of a goal-directed therapeutic protocol during transport. This will be the first test of goal-directed therapy in the transport environment. Data will be collected on pediatric SIRS patients transported by the Angel One Transport Team at Arkansas Children's Hospital before and after protocol implementation. Outcome measures will include length of hospital stay, length of intensive care unit (ICU) stay, incidence of multiple organ dysfunction syndrome (MODS), and required therapeutic interventions during ICU stay (TISS-28 scores). In addition, NIRS (Near-Infrared Spectroscopy) monitoring will be used as a cerebral and somatic oxygenation trend monitor, to determine its effectiveness as a resuscitation guide for pediatric SIRS during transport. NIRS trends are useful as a surrogate marker for systemic venous saturations, known to decrease with severe SIRS.


Recruitment information / eligibility

Status Terminated
Enrollment 230
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender Both
Age group 1 Month to 17 Years
Eligibility Inclusion Criteria:

- Pediatric patients transported to Arkansas Children's Hospital by the Angel One Transport Team

- Age Group: 1 month - 17 years

- Systemic Inflammatory Response Syndrome (Age-specific SIRS criteria)

Exclusion Criteria:

- Known or suspected congenital heart disease

- Known or suspected cardiomyopathy or myocarditis

- Diabetic Ketoacidosis (DKA) as SIRS-inducing illness

- Traumatic Brain Injury (TBI) as SIRS-inducing illness

- Burn Injury as SIRS-inducing illness

- Patients with known or suspected active hemorrhage

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • SIRS (Systemic Inflammatory Response Syndrome(
  • Systemic Inflammatory Response Syndrome

Intervention

Procedure:
Goal-directed Therapeutic Protocol
A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.

Locations

Country Name City State
United States Arkansas Children's Hospital Little rock Arkansas

Sponsors (2)

Lead Sponsor Collaborator
Arkansas Children's Hospital Research Institute Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Multiple Organ Dysfunction Computed utilizing PELOD scores. ICU Admission to ICU Discharge No
Primary Required ICU Interventions Utilizing TISS-28 Scores ICU Admission to ICU Discharge No
Primary Hospital Length of Stay Subjects will be followed from hospital admission to hospital discharge. Hospital Admission to Hospital Discharge No
Secondary Changes in cerebral and somatic oxygenation Utilizing NIRS Technology During Inter-facility Transport (Average) No